Proteomics studies in inner ear disorders: pathophysiology and biomarkers

Alawieh, Ali; Mondello, Stefania; Kobeissy, Firas; Shibbani, Kamel; Bassim, Marc K.

doi:10.1586/14789450.2015.1024228

Cited by 15 publications

(19 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By a shotgun proteomics approach, the identification of proteins with high sensitivity is enabled (17). Mass spectrometric (MS) analyses have been successfully used for auditory proteomics and require a more concerted effort for biomarker identification (18). In addition, sophisticated methods for perilymph sampling (19) have revolutionized the field of otology, offering precious biofluid samples for analysis.…”

Section: Biological Markersmentioning

confidence: 99%

Biomarkers in Vestibular Schwannoma–Associated Hearing Loss

et al. 2019

View full text Add to dashboard Cite

Vestibular schwannomas (VSs) are benign tumors composed of differentiated neoplastic Schwann cells. They can be classified into two groups: sporadic VS and those associated with neurofibromatosis type 2 (NF2). VSs usually grow slowly, initially causing unilateral sensorineural hearing loss (HL) and tinnitus. These tumors cause HL both due to compression of the auditory nerve or the labyrinthine artery and due to the secretion of different substances potentially toxic to the inner ear or the cochlear nerve. As more and more patients are diagnosed and need to be managed, we are more than ever in need of searching for biomarkers associated with these tumors. Owing to an unknown toxic substance generated by the tumor, HL in VS may be linked to a high protein amount of perilymph. Previous studies have identified perilymph proteins correlated with tumor-associated HL, including μ-Crystallin (CRYM), low density lipoprotein receptor-related protein 2 (LRP2), immunoglobulin (Ig) γ-4 chain C region, Ig κ-chain C region, complement C3, and immunoglobulin heavy constant γ 3. Besides, the presence of specific subtypes of heat shock protein 70 has been suggested to be associated with preservation of residual hearing. It has been recently demonstrated that chemokine receptor-4 (CXCR4) is overexpressed in sporadic VS as well as in NF2 tumors and that hearing disability and CXCR4 expression may be correlated. Further, the genetic profile of VS and its relationship with poor hearing has also been studied, including DNA methylation, deregulated genes, growth factors, and NF2 gene mutations. The knowledge of biomarkers associated with VS would be of significant value to maximize outcomes of hearing preservation in these patients.

show abstract

Section: Biological Markersmentioning

confidence: 99%

Biomarkers in Vestibular Schwannoma–Associated Hearing Loss

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Since 1966, researchers have been analyzing the perilymph profile to increase knowledge of hearing loss, beginning with animals. Since then, proteomic studies on human perilymph have been performed successfully [15,16,20,21,22]. Thalmann et al [21] were the pioneers in this field, using high-resolution, two-dimensional electrophoresis to study protein profiles in human perilymph.…”

Section: Discussionmentioning

confidence: 99%

Relationship between Metabolomics Profile of Perilymph in Cochlear-Implanted Patients and Duration of Hearing Loss

et al. 2019

View full text Add to dashboard Cite

Perilymph metabolomic analysis is an emerging innovative strategy to improve our knowledge of physiopathology in sensorineural hearing loss. This study aims to develop a metabolomic profile of human perilymph with which to evaluate the relationship between metabolome and the duration of hearing loss. Inclusion criteria were eligibility for cochlear implantation and easy access to the round window during surgery; patients with residual acoustic hearing in the ear to be implanted were excluded. Human perilymph was sampled from 19 subjects during cochlear implantation surgery. The perilymph analysis was performed by Liquid Chromatography−High-Resolution Mass and data were analyzed by supervised multivariate analysis based on Partial Least-Squares Discriminant Analysis and univariate analysis. Samples were grouped according to their median duration of hearing loss. We included the age of patients as a covariate in our models. Statistical analysis and pathways evaluation were performed using Metaboanalyst. Nineteen samples of human perilymph were analyzed, and a total of 106 different metabolites were identified. Metabolomic profiles were significantly different for subjects with ≤12 or >12 years of hearing loss, highlighting the following discriminant compounds: N-acetylneuraminate, glutaric acid, cystine, 2-methylpropanoate, butanoate and xanthine. As expected, the age of patients was also one of the main discriminant parameters. Metabolic signatures were observed for duration of hearing loss. These findings are promising steps towards illuminating the pathophysiological pathways associated with etiologies of sensorineural hearing loss, and hold open the possibilities of further explorations into the mechanisms of sensorineural hearing loss using metabolomic analysis.

show abstract

“…Alawieh et al reviewed the proteomic profile of the inner ear, resulting in the identification of about 50 proteins. The profiling of plasma samples obtained from MD patients showed overexpression of factor H and B, fibrinogen α and γ, β actin, and pigment epithelium-derived factor proteins [34]. Concurrently, there was an underexpression of β-2 lipoprotein I, vitamin D binding proteins, and apo-lipoprotein I compared with controls.…”

Section: Biomarkers Of Inflammation Antibody Biomarkersmentioning

confidence: 90%

Biomarkers for Inner Ear Disorders: Scoping Review on the Role of Biomarkers in Hearing and Balance Disorders

et al. 2020

View full text Add to dashboard Cite

The diagnostics of inner ear diseases are primarily functional, but there is a growing interest in inner ear biomarkers. The present scoping review aimed to elucidate gaps in the literature regarding the definition, classification system, and an overview of the potential uses of inner ear biomarkers. Relevant biomarkers were categorized, and their possible benefits were evaluated. The databases OVID Medline, EMBASE, EBSCO COINAHL, CA PLUS, WOS BIOSIS, WOS Core Collection, Proquest Dissertations, Theses Global, PROSPERO, Cochrane Library, and BASE were searched using the keywords “biomarker” and “inner ear”. Of the initially identified 1502 studies, 34 met the inclusion criteria. The identified biomarkers were classified into diagnostic, prognostic, therapeutic, and pathognomonic; many were detected only in the inner ear or temporal bone. The inner-ear-specific biomarkers detected in peripheral blood included otolin-1, prestin, and matrilin-1. Various serum antibodies correlated with inner ear diseases (e.g., anti-type II collagen, antinuclear antibodies, antibodies against cytomegalovirus). Further studies are advised to elucidate the clinical significance and diagnostic or prognostic usage of peripheral biomarkers for inner ear disorders, filling in the literature gaps with biomarkers pertinent to the otology clinical practice and integrating functional and molecular biomarkers. These may be the building blocks toward a well-structured guideline for diagnosing and managing some audio-vestibular disorders.

show abstract

Proteomics studies in inner ear disorders: pathophysiology and biomarkers

Cited by 15 publications

References 87 publications

Biomarkers in Vestibular Schwannoma–Associated Hearing Loss

Biomarkers in Vestibular Schwannoma–Associated Hearing Loss

Relationship between Metabolomics Profile of Perilymph in Cochlear-Implanted Patients and Duration of Hearing Loss

Biomarkers for Inner Ear Disorders: Scoping Review on the Role of Biomarkers in Hearing and Balance Disorders

Contact Info

Product

Resources

About